Dr. Reddy’s Aurigene Achieves 100% Response in Phase 1 CAR-T Therapy for Multiple Myeloma

Dr. Reddy’s Laboratories Limited announced that Aurigene Oncology Limited, its wholly-owned subsidiary and a clinical-stage biotech company focused on novel cancer therapies, has presented the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study. This trial marks India’s first foray into autologous BCMA-directed CAR-T cell therapy for patients with relapsed/refractory multiple myeloma.

The initial results of the study were based on data from the first eight patients. These patients had undergone significant prior treatments, with a median of 5.5 previous therapy lines. Many had also undergone transplants and experienced disease progression post-transplant. Remarkably, all eight patients (100%) showed a clinical response, with five (62.5%) achieving a stringent complete response. In terms of safety, no high-grade events related to Cytokine Release Syndrome (CRS) or neurotoxicity were reported, indicating a promising safety profile.

Following the Phase 1 results, India’s regulatory body, the Drugs Controller General of India (DCGI), has approved the commencement of Phase 2 trials. The Phase 1 results were recently presented at the 21st Annual Meeting of the International Myeloma Society held in Rio De Janeiro, Brazil.

Dr Murali Ramachandra, CEO of Aurigene Oncology Limited, said, “The results from the trial in heavily pre-treated relapsed refractory myeloma patients are very exciting for us in India. We are thrilled with the data, as the drug could be transformative for Indian patients with myeloma”

This achievement is a significant milestone in cancer treatment for Indian patients and reflects Aurigene’s commitment to pioneering innovative therapeutic solutions.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.